Rheumatoid Arthritis – Current Treatment – Current Treatment: Physician Insights – Rheumatoid Arthritis (EU5)

Many established therapies are available to treat rheumatoid arthritis (RA). Tumor necrosis factor-alpha (TNF-alpha) inhibitors are the most widely used class of agents after conventional disease-modifying anti-rheumatic drugs (cDMARDs) for treating the disease. However, approximately half of the patients fail to respond adequately to first-line therapy and quickly move to second-line treatment. Even in responders, the therapeutic benefit of these agents tends to diminish over time. However, in the past decade, the RA market has experienced a new wave of growth, driven by the entry of biosimilars and current and emerging agents with alternative mechanisms of action, which provide new treatment options for those patients who respond inadequately to earlier lines of treatment including TNF-α inhibitors.The availability of these new therapies is influencing physicians’ prescribing practices and reshaping the overall RA treatment landscape.This report offers insight into rheumatologists’ prescribing patterns, attitudes and perceptions, and current and anticipated use of various products.

Questions answered

• Which drug classes are the patient-share leaders in each line of therapy? How are the various biological agents positioned in surveyed physicians’ RA treatment algorithm?
• What are the most influential drivers and constraints influencing physicians’ treatment decisions for RA?
• How long do patients stay on a therapy? What factors drive therapy discontinuation and switching?
• How and why have rheumatologists’ prescribing practices changed in the past year? What changes are they anticipating in the coming year?

Markets covered: France, Germany, Italy, Spain, and the United Kingdom

Primary research: 250 rheumatologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom.

Key drugs: Enbrel, Humira, Remicade, Cimzia, Simponi, Orencia, Actemra, MabThera, Olumiant, Xeljanz, Rinvoq, Jyseleca

Product description

Through survey data from EU5 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
• Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.